These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 28883281)

  • 21. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.
    Fujiwara M; Anstadt EJ; Clark RB
    Front Immunol; 2017; 8():42. PubMed ID: 28184224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
    Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
    Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
    Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Status in Refractory Lymphomas.
    Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
    PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.
    Janakiram M; Pareek V; Cheng H; Narasimhulu DM; Zang X
    Immunotherapy; 2016 Jun; 8(7):809-19. PubMed ID: 27349980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sense transcripts originated from an internal part of the human retrotransposon LINE-1 5' UTR.
    Alexandrova EA; Olovnikov IA; Malakhova GV; Zabolotneva AA; Suntsova MV; Dmitriev SE; Buzdin AA
    Gene; 2012 Dec; 511(1):46-53. PubMed ID: 22982412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
    Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
    Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.
    Concha-Benavente F; Srivastava RM; Trivedi S; Lei Y; Chandran U; Seethala RR; Freeman GJ; Ferris RL
    Cancer Res; 2016 Mar; 76(5):1031-43. PubMed ID: 26676749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of immune evasion in breast cancer.
    Wang M; Zhang C; Song Y; Wang Z; Wang Y; Luo F; Xu Y; Zhao Y; Wu Z; Xu Y
    Onco Targets Ther; 2017; 10():1561-1573. PubMed ID: 28352189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune pressures drive the promoter hypermethylation of neoantigen genes.
    Yi M; Dong B; Chu Q; Wu K
    Exp Hematol Oncol; 2019; 8():32. PubMed ID: 31799063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: Signaling pathways behind immune evasion and therapy resistance.
    Martin-Orozco E; Wang L; Chatterjee S; Hanks BA
    Front Immunol; 2022; 13():1104167. PubMed ID: 36569846
    [No Abstract]   [Full Text] [Related]  

  • 35. Correction for Vannini et al., αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion.
    Proc Natl Acad Sci U S A; 2019 Oct; 116(43):21950. PubMed ID: 31611407
    [No Abstract]   [Full Text] [Related]  

  • 36. Correction: PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.
    Jang HR; Shin SB; Kim CH; Won JY; Xu R; Kim DE; Yim H
    Cell Death Differ; 2022 Oct; 29(10):2106. PubMed ID: 34404920
    [No Abstract]   [Full Text] [Related]  

  • 37. Hippo pathway as another oncogenic mediator to promote immune evasion by PD-L1 signaling.
    Hong SH
    J Thorac Dis; 2019 Mar; 11(Suppl 3):S318-S321. PubMed ID: 30997208
    [No Abstract]   [Full Text] [Related]  

  • 38. Extracellular Vesicles Containing PD-L1 Contribute to Immune Evasion in Glioblastoma.
    Lubin JA; Zhang RR; Kuo JS
    Neurosurgery; 2018 Sep; 83(3):E98-E100. PubMed ID: 30125027
    [No Abstract]   [Full Text] [Related]  

  • 39. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
    Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
    Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
    Kataoka K
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):967-971. PubMed ID: 29138368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.